nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CHRM2—forebrain—attention deficit hyperactivity disorder	0.00624	0.108	CbGeAlD
Dicyclomine—CHRM1—forebrain—attention deficit hyperactivity disorder	0.00568	0.0981	CbGeAlD
Dicyclomine—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.00528	0.0911	CbGeAlD
Dicyclomine—CHRM3—forebrain—attention deficit hyperactivity disorder	0.00508	0.0878	CbGeAlD
Dicyclomine—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.0048	0.083	CbGeAlD
Dicyclomine—CHRM2—nervous system—attention deficit hyperactivity disorder	0.00339	0.0585	CbGeAlD
Dicyclomine—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.00326	0.0563	CbGeAlD
Dicyclomine—CHRM2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.0031	0.00329	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00308	0.00327	CbGpPWpGaD
Dicyclomine—CHRM1—nervous system—attention deficit hyperactivity disorder	0.00308	0.0533	CbGeAlD
Dicyclomine—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.00297	0.0513	CbGeAlD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00281	0.00299	CbGpPWpGaD
Dicyclomine—CHRM3—nervous system—attention deficit hyperactivity disorder	0.00276	0.0477	CbGeAlD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00275	0.00292	CbGpPWpGaD
Dicyclomine—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00275	0.00292	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00274	0.00291	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00272	0.00288	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.00271	0.00287	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00269	0.00286	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00269	0.00285	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00266	0.00282	CbGpPWpGaD
Dicyclomine—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.00266	0.0459	CbGeAlD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00262	0.00278	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00262	0.00278	CbGpPWpGaD
Dicyclomine—CHRM2—brain—attention deficit hyperactivity disorder	0.00259	0.0447	CbGeAlD
Dicyclomine—CHRM3—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00249	0.00265	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00247	0.00262	CbGpPWpGaD
Dicyclomine—CHRM1—brain—attention deficit hyperactivity disorder	0.00236	0.0407	CbGeAlD
Dicyclomine—CHRM2—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00232	0.00246	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00218	0.00231	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00217	0.00231	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.00216	0.0023	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.00216	0.0023	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00215	0.00228	CbGpPWpGaD
Dicyclomine—CHRM3—brain—attention deficit hyperactivity disorder	0.00211	0.0364	CbGeAlD
Dicyclomine—CHRM1—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.0021	0.00222	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00209	0.00222	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00209	0.00222	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00207	0.00219	CbGpPWpGaD
Dicyclomine—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.00207	0.0357	CbGeAlD
Dicyclomine—CHRM1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00205	0.00218	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00205	0.00217	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.00203	0.00216	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.00203	0.00215	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00203	0.00215	CbGpPWpGaD
Dicyclomine—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.00199	0.0344	CbGeAlD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00197	0.00209	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00191	0.00202	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0019	0.00202	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.0019	0.00202	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.00189	0.00201	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00188	0.002	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00187	0.00198	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00186	0.00198	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00184	0.00196	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00183	0.00194	CbGpPWpGaD
Dicyclomine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00181	0.00192	CbGpPWpGaD
Dicyclomine—CYP1A1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00181	0.00192	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00179	0.0019	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00177	0.00188	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00177	0.00188	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00177	0.00187	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00176	0.00187	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00176	0.00187	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00175	0.00186	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00174	0.00185	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00172	0.00182	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00171	0.00182	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00169	0.0018	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00169	0.00179	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00168	0.00178	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00167	0.00177	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00166	0.00177	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00166	0.00176	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00165	0.00175	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00164	0.00175	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00163	0.00173	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00163	0.00173	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00161	0.00171	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.0016	0.0017	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0016	0.0017	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0016	0.0017	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00158	0.00168	CbGpPWpGaD
Dicyclomine—CYP1A1—brain—attention deficit hyperactivity disorder	0.00158	0.0273	CbGeAlD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00155	0.00165	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00155	0.00164	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00153	0.00163	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00152	0.00161	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00151	0.00161	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.0015	0.00159	CbGpPWpGaD
Dicyclomine—CYP1A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00147	0.00156	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00147	0.00156	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00147	0.00156	CbGpPWpGaD
Dicyclomine—CYP1A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00146	0.00155	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00145	0.00154	CbGpPWpGaD
Dicyclomine—CYP1A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00145	0.00154	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00144	0.00153	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00144	0.00153	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00143	0.00151	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00143	0.00151	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00142	0.00151	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00142	0.00151	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00142	0.0015	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00141	0.0015	CbGpPWpGaD
Dicyclomine—CHRM1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00141	0.00149	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0014	0.00149	CbGpPWpGaD
Dicyclomine—CHRM3—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.0014	0.00149	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00133	0.00141	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00133	0.00141	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00131	0.00139	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00126	0.00133	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00125	0.00133	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00124	0.00132	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00124	0.00132	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00123	0.0013	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00118	0.00126	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00118	0.00125	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00117	0.00124	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00116	0.00123	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00116	0.00123	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00116	0.00123	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00115	0.00122	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00114	0.00122	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00114	0.00121	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00112	0.00119	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00112	0.00118	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00111	0.00117	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.0011	0.00117	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.0011	0.00116	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00109	0.00115	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00109	0.00115	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00109	0.00115	CbGpPWpGaD
Dicyclomine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00108	0.00115	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00108	0.00115	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00107	0.00114	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00107	0.00114	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00107	0.00114	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00107	0.00114	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00106	0.00113	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00105	0.00112	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00105	0.00111	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00104	0.0011	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00101	0.00107	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00101	0.00107	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000999	0.00106	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000947	0.001	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000944	0.001	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000935	0.000992	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000931	0.000988	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000928	0.000985	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000919	0.000976	CbGpPWpGaD
Dicyclomine—CYP1A1—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000902	0.000957	CbGpPWpGaD
Dicyclomine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000883	0.000937	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00085	0.000902	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000804	0.000853	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000801	0.000851	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000793	0.000842	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000757	0.000804	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000739	0.000785	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000737	0.000782	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00073	0.000775	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00073	0.000774	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000728	0.000772	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000721	0.000765	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000709	0.000753	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000707	0.00075	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.000703	0.000746	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000703	0.000746	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.0007	0.000743	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.0007	0.000743	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000694	0.000736	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000653	0.000693	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000651	0.000691	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000645	0.000684	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000638	0.000677	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000636	0.000675	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000635	0.000674	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000633	0.000672	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000633	0.000671	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000631	0.000669	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00063	0.000669	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000627	0.000665	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000624	0.000663	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000622	0.00066	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000622	0.00066	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00062	0.000658	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00062	0.000658	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000614	0.000652	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000614	0.000652	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000614	0.000652	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000612	0.00065	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00061	0.000648	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000608	0.000646	CbGpPWpGaD
Dicyclomine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.000608	0.000645	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000606	0.000643	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000602	0.000639	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000601	0.000638	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000593	0.00063	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000591	0.000628	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000586	0.000622	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000574	0.00061	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000573	0.000608	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000572	0.000607	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00057	0.000605	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000567	0.000602	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000565	0.000599	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000565	0.000599	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000563	0.000597	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000558	0.000592	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000557	0.000592	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000556	0.00059	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000551	0.000584	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000523	0.000555	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000523	0.000555	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00052	0.000551	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000518	0.00055	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000514	0.000546	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000513	0.000544	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000478	0.000507	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000431	0.000458	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00043	0.000456	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000426	0.000452	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000418	0.000443	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000415	0.000441	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000415	0.000441	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000408	0.000433	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000401	0.000425	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000399	0.000424	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000398	0.000422	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000396	0.00042	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00038	0.000403	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000377	0.0004	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000376	0.000399	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000372	0.000395	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000364	0.000386	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000363	0.000385	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000359	0.000381	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00035	0.000372	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000349	0.000371	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000346	0.000367	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000339	0.00036	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000338	0.000359	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000335	0.000356	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000334	0.000354	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000333	0.000353	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000332	0.000352	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000329	0.00035	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000329	0.00035	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000328	0.000349	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000325	0.000345	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000317	0.000336	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000316	0.000335	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000314	0.000334	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000307	0.000326	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000306	0.000325	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000303	0.000322	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000251	0.000267	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00025	0.000265	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000242	0.000257	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000215	0.000228	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000214	0.000227	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000212	0.000225	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	0.000136	0.000144	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000114	0.000121	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000114	0.00012	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000112	0.000119	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000108	0.000114	CbGpPWpGaD
